Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Mechanism/indication claims are partially consistent with the provided label sections, but multiple substantive claims about insulin sensitivity, hepatic glucose production, and insurance coverage/cost are not supported by the supplied prescribing information. No dosage, contraindications, boxed warnings, or safety/monitoring content was provided for evaluation.
Category Scores
Accurate Statements
Ozempic (semaglutide) is prescribed for the treatment of type 2 diabetes.
1 INDICATIONS AND USAGE (adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus)
Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist.
11 DESCRIPTION; 12 CLINICAL PHARMACOLOGY (12.1) (Semaglutide acts as a GLP-1 receptor agonist)
Ozempic works by mimicking the action of a natural hormone in the body.
12 CLINICAL PHARMACOLOGY (12.1) (GLP-1 is a physiological hormone; semaglutide is a GLP-1 receptor agonist)
Ozempic helps to regulate blood sugar levels.
1 INDICATIONS AND USAGE; 12 CLINICAL PHARMACOLOGY (12.1) (improve glycemic control; reduces blood glucose)
Unsupported Statements
Ozempic improves insulin sensitivity.
The provided label sections describe insulin secretion and glucagon secretion but do not mention insulin sensitivity.
Ozempic reduces the production of glucose in the liver.
The provided label sections do not describe reduction of hepatic glucose production.
In the United States, Ozempic is a prescription medication that is typically covered by most insurance plans, including Medicare and Medicaid.
No insurance coverage statements (Medicare/Medicaid/commercial) are present in the supplied label sections.
Ozempic is covered by most commercial insurance plans, including UnitedHealthcare, Aetna, and Cigna.
No commercial insurance coverage or named insurers are present in the supplied label sections.
Ozempic coverage levels and copayment requirements may vary depending on the specific insurance plan and provider.
No payer coverage/cost/coplay statements are present in the supplied label sections.
Medicare Part D covers Ozempic as a Tier 2 medication.
No Medicare Part D formulary tier information is present in the supplied label sections.
Patients may need to pay a copayment of $20-$50 per prescription for Ozempic under Medicare Part D.
No copayment amount information is present in the supplied label sections.
Medicaid also covers Ozempic.
No Medicaid coverage statements are present in the supplied label sections.
Medicaid coverage levels and copayment requirements for Ozempic may vary depending on the state and provider.
No Medicaid cost/coverage variability statements are present in the supplied label sections.
Private insurance plans may cover Ozempic.
No private insurance coverage statements are present in the supplied label sections.
The level of coverage and copayment requirements for Ozempic may vary depending on the specific private plan and provider.
No copayment/coverage variability statements are present in the supplied label sections.
The average cost of Ozempic without insurance is around $1,300 per month.
No pricing/cost information is present in the supplied label sections.
With insurance coverage, the Ozempic copayment may be significantly lower.
No copayment guidance or relative cost statements are present in the supplied label sections.
Contradictions
Important Omissions
Dose, administration details (including titration/starting dose, injection instructions, missed dose guidance) and safety content (contraindications, boxed warning, warnings/precautions, adverse reactions, monitoring).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Multiple claims are not supported by the provided label (insurance/cost statements and mechanistic specifics like insulin sensitivity and hepatic glucose production). While these may not directly alter dosing from the label evidence provided, unsupported mechanistic claims and lack of safety/administration evaluation limit on-label accuracy.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several claims (insulin sensitivity, hepatic glucose production, and insurance/cost/Part D/Medicaid/copayment details) are not supported by the supplied prescribing information.
Suggested Improvement
Limit claims to on-label content in the provided sections (indications and labeled mechanism). Remove or qualify unsupported insurance coverage/cost statements and mechanistic assertions not present in the label text provided.